{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-139510","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.341324+00:00","generated_at":"2026-06-01T22:51:06.152070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF","bullets":["Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.","Cash $12.0M at March 31, 2024; after May 2024 $20M offering, expects to fund operations into H2 2025.","Positive Cohort 1 data for LTI-03 in IPF: statistically significant in 3 of 8 biomarkers; no SAEs reported.","Topline results from high-dose Cohort 2 expected Q3 2024; also Brian Windsor appointed President and CEO in March."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-139510","json":"https://secwatch.observer/filing/0001193125-24-139510.json","markdown":"https://secwatch.observer/filing/0001193125-24-139510.md","text":"https://secwatch.observer/filing/0001193125-24-139510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/0001193125-24-139510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/d825172d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:51:06.152070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18627591e3d403767a584cc609240d6d85620c64","claim":"Rein Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter, EPS The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte.","evidence_excerpt":"Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/0001193125-24-139510-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter"},{"label":"EPS","value":"The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}